Nephrology really took an amazing turn this Kidney week in
2017. Positive trials, positive news and amazing things are happening for
everyone involved in renal care.
First and foremost, the high impact clinical trials in 2017
ASN Kidney week revealed several positive trials.
The
REPRISE study showed the impressive promise of use of tolvaptan in late
stage ADPKD. The liver related side
effects were minimal. Hope to see this in clinical practice soon
The MENTOR trial that compared cyclosporine to rituximab for
PLA2R membranous GN showed rituximab to be non inferior with lower rate of
adverse effects. Looks like rituximab will be changing the treatment paradigm
in membranous GN treatment.
Is contrast nephropathy dead? No not really. A randomized
controlled trial showed that intra arterial contrast studies are more likely to
cause contrast nephropathy compared to intra-venous, but both did have a
incidence of contrast nephropathy.
A novel agent called QPI-1002 showed significant promise in
decreasing AKI post CABG in high risk population.
Bardoxolone Methyl Improved GFR Measured by
Standard Inulin Clearance: The TSUBAKI Study in Japan. The return of Bard!!
Another positive note: The GW-ASN fellows
survey showed an upswing in job opportunities for our fellows in training. https://www.asn-online.org/education/training/workforce/
Finally, social media nephrology Guru Joel
Topf wins Robert Narins award with an amazing video presentation done by ASN.
No comments:
Post a Comment